Invention Grant
- Patent Title: Hepatitis C virus inhibitors
-
Application No.: US14254265Application Date: 2014-04-16
-
Publication No.: US09676802B2Publication Date: 2017-06-13
- Inventor: Yao-Ling Qiu , Hui Cao , Xiaowen Peng , Zhigang Chen , Yat Sun Or
- Applicant: ENANTA PHARMACEUTICALS, INC.
- Applicant Address: US MA Watertown
- Assignee: ENANTA PHARMACEUTICALS, INC.
- Current Assignee: ENANTA PHARMACEUTICALS, INC.
- Current Assignee Address: US MA Watertown
- Agency: Elmore Patent Law Group, P.C.
- Agent Edgar W. Harlan; Carolyn S. Elmore
- Main IPC: A01N43/56
- IPC: A01N43/56 ; A61K31/415 ; C07F9/6561 ; A61K31/426 ; C07D498/08 ; C07D498/18 ; C07D519/00 ; A61K38/21 ; A61K31/13 ; A61K31/7056 ; A61K38/55 ; A61K31/4188 ; A61K31/4196 ; A61K31/422 ; A61K31/4245 ; A61K31/427 ; A61K31/428 ; A61K31/4439 ; A61K31/454 ; A61K31/4709 ; A61K31/496 ; A61K31/506 ; A61K31/5377 ; A61K31/675 ; A61K45/06

Abstract:
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—Z—W (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Public/Granted literature
- US20140308243A1 HEPATITIS C VIRUS INHIBITORS Public/Granted day:2014-10-16
Information query
IPC分类: